投稿コメント一覧 (375コメント)

  • 4-Oct-18
    Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

    Celyad to Present CYAD-01 Solid Tumor Clinical Updates and Pre-Clinical Pipeline Data at the 2018 SITC Annual Meeting
    The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR (CYAD-01) generates CAR-T cells resistant to target driven fratricide and improves CYAD-01 cell persistence in vivo
    Date & Time: November 9, 12:45 – 2:15 p.m. and 6:30 – 8 p.m.

  • 2018/10/01 06:36

    Just-Announced U.S. and Cuba Biopharma Venture Sees Fruit in Lung Cancer Study
    Published: Sep 27, 2018
    A three-year-old cancer research alliance between U.S. and Cuban scientists is bearing fruit. A Cuban-developed lung cancer treatment combined with Bristol-Myers Squibb’s anti-PDL1 Opdivo shows promise in treating patients who would not likely benefit from immune checkpoint inhibition

  • 2018/09/14 06:49

    Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Morgan Stanley 16th Annual Global Healthcare Conference (Transcript)
    Sep. 13, 2018 3:24 PM

  • 2018/09/06 22:56

    SeekingAlpha 9/6/2018
    •BMS-986036, a pegylated human fibroblast growth factor-21 analogue, is an investigative metabolism modulator drug candidate in mid-stage clinical trials for NASH fibrosis and cirrhosis.
    •FGF21 is prevalent in metabolically active tissues, liver, pancreas, and adipose tissue, where it positively regulates glucose and lipid metabolism.
    •BMS-986036 could be a likely source for new organic growth in future years given its promising preliminary data for NASH, a heterogeneous disease with an addressable market of >$30B.
    •NASH is a progressive chronic liver disease without therapeutic options that have been projected to surpass HCV infection as the leading cause of liver transplant in the US beginning in 2020.

  • カイプロリス
    FiercePharma 8/31/2018
    Can Amgen's new-and-improved Kyprolis kick-start myeloma sales?

  • 試験と実治療比較:患者年齢分布
    Aero Data Lab
    Populations in Anti-PD1 Immunotherapy Trials vs. Real World Patients
    Added: August 26, 2018

  • 事実を知らせるメディア:
    国際医薬品情報‏ @IPI_editors · 2時間

    モトリオン‏ @motorion

    <東証>小野薬が続落 オプジーボの価格引き下げを嫌気:日本経済新聞

    山田創‏ @So_Yamada_ · 8月22日

  • 国際医薬品情報‏

  • fuj***** さん


  • Bristol-Myers to sell Opdivo in China at half the U.S. price
    Aug. 21, 2018 1:30 PM SA News Editor

  • 小細胞肺癌
    they(BMSvsMerck) are still fighting for every edge they can get looking for a comeback to the top spot.

    BMS PRより


    現在SCLC患者を対象として、ニボルマブ単剤療法、ニボルマブとイピリムマブの併用療法、プラセボ対照の3群を比較するフェーズ3のCheckMate 451試験が進行中である。
    Estimated Primary Completion Date : September 20, 2018


    cancerinfo.tri-kobe.org > ... > がん情報要約 > 治療(成人

  • Celyadテンバガー候補

    Par Virgil Meyre | investir.fr | Le 14/08/18
    les perspectives de la biotech sont une nouvelle fois décuplées.

    L’autorisation de la FDA (Food & Drug Administration), l’autorité sanitaire américaine, de lancer le premier programme clinique allogénique ne faisant pas appel à de l’édition du génome (Cyad 101), vient s’ajouter à une série de bonnes nouvelles. Grâce à sa récente levée de fonds ainsi qu’à la signature de plusieurs partenariats, la capacité financière de Celyad s’est renforcée. Le groupe a par ailleurs consolidé sa direction avec l’arrivée du docteur Margo Roberts, ex-directrice scientifique de Kite Pharma, au conseil d’administration, et celle de Filippo Petit de la banque Wells Fargo au poste de directeur financier.


  • 2018/08/15 07:29

    EPVantage August 14, 2018
    Most valuable unpartnered assets reveal a changing of the guard
    Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.

    オンコロ 2017.03.04 

  • Aug. 14, 2018 /PRNewswire/ --
    Array BioPharma Inc. today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs.
    Array is developing binimetinib in combination with PD-1/PD-L1 checkpoint inhibitors and previously announced separate, strategic collaborations with Bristol-Myers Squibb, Merck and Pfizer.
    Each collaboration is pursuing a different rationally designed clinical approach.
    Array has granted Ono Pharmaceutical exclusive rights to commercialize both products in Japan and South Korea
    Japan's Pharmaceuticals and Medical Devices Agency has accepted the Manufacturing and Marketing Approval applications submitted by Ono Pharmaceutical Co, Ltd.

  • 補足
    EPVantage August 10, 2018
    Another study, Bristol’s Checkmate-451, focuses on first-line maintenance.

    Last Update Posted : August 1, 2018
    Estimated Primary Completion Date : September 20, 2018

  • カナダの小さな州:Prince Edward Island でも
    Melanoma Network‏
    Amazing news. Opdivo listed in PEI as August 1st - Q4W is available as well
    •Opdivo is being added for the treatment of unresectable or metastatic melanoma BRAF wild-type melanoma; advanced or metastatic non-small cell lung cancer; advanced or metastatic renal cell carcinoma.

  • Opdivo+Cabiralizumab:膵がん

    Five Prime Therapeutics Announces Second Quarter 2018 Financial Results
    • Cabiralizumab continues to advance in randomized Phase 2 trial in pancreatic cancer
    August 08, 2018 04:05 PM Eastern Daylight Time
    We are pleased with the progress across our pipeline, including BMS’s ongoing randomized Phase 2 clinical trial to evaluate cabiralizumab and OPDIVO® with and without chemotherapy as a second-line treatment in patients with advanced pancreatic cancer,” said Aron Knickerbocker, chief executive officer of Five Prime Therapeutics. Additionally, we are pleased that the first clinical candidate from our immuno-oncology research collaboration with BMS, the TIM-3 antibody BMS-986258, is now in a Phase 1/2 trial investigating it as a single agent and in combination with OPDIVO. FPA150, our first-in-class B7-H4 antibody, is receiving strong interest from investigators and is progressing well in the Phase 1 trial.”

  • Jack Allen‏ ツイート
    The effectiveness of blood Tumor Mutational Burden (bTMB) may play a key role in $BMY strategy for their IO portfolio (Opdivo/Yervoy) moving forward

    BMS:TMBバイオマーカーFoundation Medicineの研究(ロシュ)
    nature medicine 8/6/2018
    Foundation Medicine
    Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

  • Breakthrough Therapy指定:

    Aug. 7, 2018 /PRNewswire/
    Array BioPharma today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI™), in combination with binimetinib (MEKTOVI®) and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) as detected by an FDA-approved test, after failure of one to two prior lines of therapy for metastatic disease.
    BRAFV600E-mutant mCRC patients have a mortality risk more than double that of mCRC patients without the mutation,
    and currently there are
    <no therapies specifically approved for this high unmet need population.>

本文はここまでです このページの先頭へ